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ColoPulse tablets are an innovative development in the field of oral dosage forms character-
ized by a distal ileum and colon-specific release. Previous studies in humans showed
release in the ileo-colonic region, but the relationship between gastrointestinal pH and
release was not experimentally proven in vivo. This information will complete the in vivo
release-profile of ColoPulse tablets.
Materials and Methods
Release from ColoPulse tablets was studied in 16 healthy volunteers using the dual label
isotope strategy. To determine gastrointestinal pH profiles and transit times the IntelliCap
system was used. A ColoPulse tablet containing 13C-urea and an uncoated, immediate
release tablet containing 15N2-urea were taken simultaneously followed by a standardized
breakfast after three hours. Five minutes after intake of the tablets the IntelliCap capsule
was swallowed and pH was measured until excretion in the feces. Breath and urine samples
were collected for isotope analysis.
Results
Full analysis could be performed in 12 subjects. Median bioavailability of 13C -urea was
82% (95% CI 74–94%, range 61–114%). The median lag time (5% release of 13C) was 5:42
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h (95% CI 5:18–6:18 h, range 2:36–6:36 h,) There was no statistically significant difference
between lag time based on isotope signal and colon arrival time (CAT) based on pH
(median 5:42 vs 5:31 h p = 0.903). In all subjects an intestinal pH value of 7.0 was reached
before release of 13C from the ColoPulse tablet occurred.
Discussion and Conclusions
From the combined data from the IntelliCap system and the 13C -isotope signal it can be
concluded that release from a ColoPulse tablet in vivo is not related to transit times but
occurs in the ileo-colonic region after pH 7.0 is reached. This supports our earlier findings
and confirms that the ColoPulse system is a promising delivery system for targeting the dis-




Distal ileum and Colon-specific delivery of medicines is clinically relevant because their effi-
cacy can be improved, side effects can be reduced and the bioavailability of drugs that are
metabolized or poorly absorbed in the higher parts of the small intestine can be enhanced. This
offers interesting perspectives for the treatment of for instance inflammatory bowel diseases
with peptides [1].
In the literature different strategies for colon-specific delivery have been described. They
include pH-responsive systems, time-based systems and systems triggered by the colon flora,
as well as combinations of such systems [1,2]. The recently developed ColoPulse technology is
a promising pH-responsive system being able to specifically deliver the active substance to
the ileo-colonic region. Because of the non-percolating incorporation of a super-disintegrant in
the coating, by which a more reliable and pulsatile release is achieved, it differs from other pH-
responsive systems. The dissolution of this coating is triggered by the physiologically occurring
increase in pH from 5.5 in the upper small intestine to 7.5 in the ileo-colonic region [3].
Until now bioavailability from ColoPulse dosage forms has been studied in healthy volun-
teers and in patients with Crohn’s disease using stable isotopes of urea [4,5,6]. All studies
showed a mean total bioavailability of 13C-urea of> 76%, but the relationship between gastro-
intestinal pH and release from a ColoPulse dosage form has so far not been proven experimen-
tally in vivo. To obtain more insight in the behaviour and functioning of ColoPulse tablets and
capsules in vivo, studies on the gastrointestinal pH with the concomitant administration of a
ColoPulse tablet are justified.
In the literature different devices for gastrointestinal pH measurement have been described
[7]. They can be divided in two subgroups: the “static” devices and the “freely moving” devices.
With representatives of the first group only the oesophageal, intra-gastric or peri-mucosal
colonic pH can be measured. Their main disadvantage is the inability to measure the pH along
the entire length of the gastrointestinal tract. The second group mainly comprises pH sensitive
wireless radiotelemetry capsules (RTC). After administration of a RTC the subject is able to
perform normal daily activities. Emitted radio signals are detected by a recorder mostly worn
around the waist. If the device functions properly, measuring ends when the RTC is excreted
Ileo-Colonic Release of ColoPulse Tablets Confirmed with IntelliCap
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with the feces. Disadvantages of the RTCs used so far are the frequent loss of signals, batteries
running out of power before excretion, large pH-drift (up to approximately 1 unit) and difficul-
ties in determining the exact location of the capsule in the gastrointestinal tract. In Table 1 a
summary of the available literature on freely moving devices studied in inflammatory bowel
diseases and / or healthy volunteers is presented [8–21].
Recently a medical device for the in vivomeasurement of pH and temperature in the gastro-
intestinal tract was developed by Medimetrics (Eindhoven, The Netherlands): the IntelliCap
system [20,21]. Furthermore the system can be used for electronically controlled drug delivery
in defined sections of the gastrointestinal tract to quantify regional drug absorption [22]. It dif-
fers from the so far available freely moving RTCs by more accurate and more frequent mea-
surements, minimal signal loss, a built-in drug reservoir and improved battery power (> 72 h)
to ensure reliable and complete data acquisition. By combining diagnostic functionalities and
the capability to generate adjustable controlled drug release profiles, the IntelliCap system can
play a promising role in pharmaceutical drug profiling and formulation development.
In this paper we describe a study performed in healthy volunteers in which we studied the
relationship between gastrointestinal pH obtained with the IntelliCap system as well as the
release from a ColoPulse tablet to prove that release from a ColoPulse tablet indeed does occur
in the ileo-colonic region and after a pH value of 7.0 is reached.
Materials and Methods
Subjects
Sixteen healthy volunteers (10 male, 6 female, age 18–65) were initially included in this study
(Table 2). Participant recruitment started January 2011 and ended April 2011. Written
informed consent was obtained from all participants. They had no history of gastrointestinal
diseases or gastrointestinal surgery. None of the subjects used antibiotics or drugs influencing
the gastrointestinal transit time for at least three months prior to the start of the study. A possi-
ble Helicobacter pylori infection was excluded with a 13C-urea breath test (INFAI, Köln,
Germany).
A flowchart summarizing recruitment and analysis is shown in Fig 1.
Study-design
This bioavailability study was performed as an open-label, non-randomized, single arm clinical
trial and was part of a study described by Maurer et al [6]. The design was based on a previous
feasibility study in which two stable isotopes of urea are administered simultaneously [23].
Subjects were fasted from 8 p.m. the day before the test day. Only water, apple juice (until 11 p.
m.) and unsweetened tea without sugar were allowed. On the test day an uncoated tablet con-
taining 50 mg 15N2-urea and a ColoPulse tablet containing 50 mg
13C-urea were taken simulta-
neously at around 8 a.m. with 100 mL apple juice. Five minutes thereafter the IntelliCap
capsule was swallowed with another 100 mL apple juice. A standardized breakfast was taken
three hours after the intake of the tablets. The meal consisted of a standardized double sand-
wich and 200 mL unsweetened tea. Approximately 6 and 10 hours after tablet intake, respec-
tively lunch and dinner were taken. There were no food-restrictions for lunch and dinner
except foods rich in 13C, like corn products, cane sugar and pineapple. During the test day,
(that ended at 8 a.m. the next morning) water, apple juice and tea were the only beverages
allowed.
Sampling, administration of the tablets and IntelliCap capsule took place in a controlled
facility until 5 p.m. Thereafter subjects went home were they continued sampling of breath and
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urine according to the study protocol. All necessary information was recorded in a diary. A
summary of the study design is shown in Table 3.
Ethics statement
The study was approved by the ethical committee of the University Medical Center Groningen
(ref 2009.188 / EudraCT 2009–01347121) and was performed according to the principles of
the Declaration of Helsinki. The study has been registered in the ISRCTN register
(ISRCTN18301880). This was not done before the start of recruitment because at that time this
was not required by internal procedures and the ethical committee that approved this study.
IntelliCap system
The IntelliCap system was supplied by Medimetrics (Eindhoven, The Netherlands) and con-
sisted of a capsule and a portable unit. The size of the IntelliCap capsule was 27 x 11 mm. A
complete description including illustrations of the IntelliCap system can be found in the litera-
ture [20]. The drug reservoir was filled with normal saline solution which had no function in
this study and was not expelled from the IntelliCap capsule during the experiments.
Data were measured until excretion of the IntelliCap capsule or until the battery ran out of
power. The excretion of the IntelliCap capsule from the body had to be confirmed by collecting
the device from the stool. If the IntelliCap capsule was not retrieved within 96 hours it was
probably missed and its absence from the body was confirmed with an abdominal X-ray. No
follow up was required after retrieving the IntelliCap capsule or confirmation of its absence by
X-ray.
Analysis of pH profiles
The pH profiles were analysed for gastrointestinal landmarks (ingestion, pylorus, ileocecal
valve and excretion) using the following criteria:
▪. Ingestion: rapid and sustained rise in temperature from room to body temperature and a
rapid drop of> 3 pH units
▪. Pylorus: rapid and sustained rise of at least 3 pH units
▪. Ileocecal valve (cecum): first and rapid drop of> 0.8 pH units at least 1 h after the pylo-
rus to pH 6.5
▪. Excretion: rapid and sustained drop in temperature from body to room temperature
Gastrointestinal residence and transit times were derived from the identification of gastroin-
testinal landmarks and are defined as follows:
▪. Gastric residence time (GRT): elapsed time between ingestion and pylorus
▪. Small intestine transit time (SBTT): elapsed time between pylorus and ileocecal valve
▪. Colonic arrival time (CAT): elapsed time between ingestion and ileocecal valve
Table 2. Demographics of included subjects (healthy volunteers).
Median (range)
Sex (male / female) 10 / 6
Age (year) 27.5 (19–63)
Weight (kg) 77.0 (54.5–121.4)
doi:10.1371/journal.pone.0129076.t002
Ileo-Colonic Release of ColoPulse Tablets Confirmed with IntelliCap
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Fig 1. Flowchart.
doi:10.1371/journal.pone.0129076.g001
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▪. Colonic transit time (CTT): elapsed time between ileocecal valve and excretion
▪. Whole gut transit time (WGTT): elapsed time between ingestion and excretion
Chemicals, isotopes and coated tablets
All substances were of pharmacopoeial grade (Ph. Eur. or USP) and were obtained via a certi-
fied wholesaler as described before [6]. The stable isotopes 13C-urea and 15N2-urea (AP 99%)
were obtained from an FDA-controlled facility (Isotec, USA). Tablet cores containing 50 mg
13C- or 50 mg 15N2-urea and 25 mg caffeine were compounded in the Department of Hospital
and Clinical Pharmacy of the University Medical Center Groningen and analysed according to
the European Pharmacopoeia 7th edition
A ColoPulse coating of 13–17 mg/cm2 was applied on the tablets containing 13C-urea.The
coating was composed of a mixture of Eudragit S-100:PEG 6000:Ac-di-sol:talc in a ratio of
7:1:3:2 (w/w). The solvent was an acetone-water 97:3 mixture (w/w). Coating thickness was
determined and expressed as the amount of Eudragit S100 applied per cm2. Caffeine was added
to the 13C-urea tablet cores for quality control purposes and was used as a marker substance
for the in vitro determination of the release characteristics lag- and pulse time in the in vitro
dissolution test. Caffeine was also added to the 15N2-urea tablet cores to obtain comparable tab-
let cores, with no particular function in this tablet. All tablets, coated and uncoated, met estab-
lished pharmaceutical quality control criteria [6].
Urea-kinetics
To study the bioavailability from a ColoPulse tablet in the ileo-colonic region the difference in
kinetics and fate between 13C-urea and 15N2-urea was used. An overview of the relevant kinetic
steps can be found in Maurer et al [23,24]. Release of 13C-urea in the ileo-colonic region (ure-
ase-rich) from a ColoPulse tablet leads to in situ fermentation of 13C-urea into 13CO2 which is
subsequently exhaled in breath. The delivery of the isotope in the colon can therefore be estab-
lished by measuring the 13CO2 response in breath. Unfermented urea (i.e. release in the small
intestine, urease-poor) can be measured as the amount of 13C-urea in urine. The second stable
isotope of urea, 15N2-urea, in an uncoated tablet functions as a reference and reflects 100%
release in a urease-poor region. Release of 15N2-urea in the small intestine from an uncoated
capsule leads to recovery of 15N2-urea in urine. Bioavailability can be described by the differ-
ence between kinetics of 13C- and 15N2-urea [23,24].
Table 3. Study schedule, activities are marked with an X (T0 is 8 a.m.).








Meal X X X
Urine Sample X X X X X X X
Breath sample X X X X XX XX X XX XX XX XX XX X X X X
Return home X
doi:10.1371/journal.pone.0129076.t003
Ileo-Colonic Release of ColoPulse Tablets Confirmed with IntelliCap
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Sample collections and analysis
Breath samples were collected every 0.5–1 h up to 15 h after intake of the tablets (Table 2) and
were analysed as described before [23]. Briefly, 13C/12C isotope ratios in the CO2 of breath sam-
ples were analysed by using a validated breath 13C-analyser (Thermo Fisher Scientific, Bremen,
Germany) based on isotope ratio mass spectrometry (IRMS).
Urine samples were collected during 24 h after intake of the tablets at prescribed intervals
(Table 2) in 500 or 1000 mL containers containing an aliquot of 6M HCl. Urine volumes were
recorded and 20 mL samples were stored at -80°C until analysis. Concentrations of total 15N
and 13C were determined as described before using an elemental analyzer interfaced with
IRMS [23].
Calculations
The Percentage of the administered Dose Recovered (PDR) of 13C and 15N in each urine sam-
ple, the ratio of the PDRs 13C versus 15N (the 13C/15N-ratio), the fermented (Ffermented) and
not-fermented (Fnot-fermented) fraction of
13C urea were calculated as described before [23,24].
In short:
▪. Ffermented was calculated as the cumulative (c)PDR of 13C in breath over a 15 h time
period
▪. Fnot-fermented = cPDR 13C / cPDR 15N in a 24 h urine collection
▪. Bioavailability = Ffermented + Fnot-fermented
▪. The lag time was derived from the cPDR of 13C in breath and was defined as de time
between administration of the tablets and the time the cPDR reached the value of 5% of
cPDR at t = 15 h
All data were corrected for baseline-concentrations of 13C and 15N in breath and /or urine.
Furthermore, breath data were corrected for CO2-retention as described before [4].
Statistical procedures
This study was performed as a bioavailability study. Based on previous data on transit times of
a ColoPulse tablet a sample size of 10 patients is needed to detect a clinically relevant difference
of 15% between lag-time based on isotope-signal and colon arrival time based on pH with 80%
power and a significance level of α = 0.05 (two sided). Because this study was part of another
study [6] requiring a higher sample size and anticipating some drop-out 16 subjects were
included.
The results were evaluated by descriptive statistics with SPSS version 22. Normal distribu-
tion of the data was investigated with the Shapiro-Wilk test. The center was characterized by
the mean and standard deviation (pH-data) or the median and corresponding bootstrap based
95% confidence intervals (95% CI). The dispersion was characterized by the coefficient of vari-
ation (CV) and range because not all data were normally distributed. A (parametric) paired-
samples t-test (two tailed, α = 0.05) was used to compare the results within groups when data
were normally distributed for both variables. A (non-parametric) Wilcoxon signed rank test
was performed to compare the results when at least one of the variables was not normally dis-
tributed. Differences were considered significant when p< 0.05.
Ileo-Colonic Release of ColoPulse Tablets Confirmed with IntelliCap
PLOS ONE | DOI:10.1371/journal.pone.0129076 July 15, 2015 9 / 17
Endpoints
The endpoint was to investigate the relationship between the gastrointestinal pH-profile
obtained with the IntelliCap system and release of 13C-urea from a ColoPulse tablet and to con-
firm that release occurs in the ileo-colonic region after pH 7.0 has been reached.
Results
The results of 15 out of 16 healthy volunteers initially included in the study were evaluated (Fig
1). One volunteer could not swallow the IntelliCap capsule and was therefore excluded without
replacement. Two other subjects (6 and 15) appeared to have a prolonged gastric residence
time and the IntelliCap capsule was still in the stomach when breakfast and the following
meals were taken. Because their gastric residence time was respectively 17 and 22 h data of
these subjects were excluded from any analysis comprising transit times. Their lag time based
on the isotope signal was within the normal range. Subject 5 was also excluded from analysis
comprising lag time and bioavailability, because of a probably altered urea metabolism. This
was concluded from the fact that the cPDR 13C in breath was<6.5% after 15h combined with a
cDPR of unfermented 13C in urine of 70% at t = 24 h. The pH profile of this subject was normal
with a GRT of 0:15 h and a SBTT of 3.15 h. The coating functioned well, because the appear-
ance of 13C in the urine sample could be seen in the sample collected between t = 4 and 7 h and
not earlier. This means that 13C-urea in stead of being fermented was absorbed into the blood-
stream when it was released at the ileo-colonic region. The data from the remaining 12 subjects
were available for all analyses.
IntelliCap capsules could be recovered from the feces within 72 hours after intake in 13 out
of 15 subjects. For two subjects the temperature data indicated that the IntelliCap capsule had
left the body, but the subjects failed to retrieve it from the feces. Absence from the body was
confirmed with an abdominal X-ray. No adverse events potentially related to the IntelliCap
system were observed during the study.
In three subjects the portable unit ran out of power after circa 60 hours. This did not influ-
ence the data collection necessary for the endpoint analysis because in all subjects the Intelli-
Cap capsule already passed the cecum. However, for these subjects time of excretion and whole
gut transit time (WGTT) could not be determined.
In three other subjects the communication between the capsule and portable unit was inter-
rupted varying from 4 to 12 h because the subjects did not wear the portable unit close enough
to the body or did not wear it. This also did not influence the data collection for endpoint anal-
ysis because all interruptions occurred more than 24 h after intake, when the IntelliCap capsule
already had passed the cecum. For one of these subjects excretion, CTT and WGTT could not
be determined because excretion occurred during the period of interrupted communication.
No other loss of data was encountered in the study.
All gastrointestinal pH profiles recorded with the IntelliCap system were analysed according
to the mentioned methods. A summary of the gastrointestinal transit times is shown in Fig 2
and a representative example of a pH and temperature profile is shown in Fig 3. The residence
in the stomach, passage of the pylorus, course of pH in the small intestine and the ileocecal
valve (cecum) are all clearly visible in this figure. From Fig 2 it is obvious that there are large
inter-individual differences in transit times. For example, the colon arrival time (CAT) differs
from 3:25–8:20 h (median 5:31 h, 95% CI 4:51–5:48 h, CV 26%) and the whole gut transit time
for the IntelliCap capsule was 10:01–59:39 h (median 27:08 h, 95% CI 22:49–59:11 h, CV 52%).
Gastric residence time varied between 0:15 and 3:14 h (median 1:30 h, 95% CI 1:05–2:08 h, CV
59%). The median difference between the time when pH 7.0 was reached and the CAT was
Ileo-Colonic Release of ColoPulse Tablets Confirmed with IntelliCap
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2.26 h and in most subjects pH remained> 7.0 until the cecum was reached. A summary of
measured pH values in the stomach, small intestine and colon is shown in Fig 4.
Lag time and bioavailability of 13C-urea from a ColoPulse tablet were calculated as
described. The median lag time was 5:42 h (95% CI 5:18–6:18 h, range 2:36–6:36 h, CV 18%)
and median bioavailability was 82% (95% CI 74–94%) range 61–114%, CV 10%). More detailed
results can be found in S1 summary and in Maurer et al [6].
There was no statistically significant difference between CAT based on pH-data (IntelliCap)
and the lag time of the ColoPulse tablet based on the stable isotope signal of 13C-urea in breath
(median 5:31 vs 5:42 h, p = 0.903, parametric test). A representative example is shown in Fig 5.
Information about all subjects can be found in Fig 6.
In all subjects a pH value of 7.0 was reached before release of 13C from the ColoPulse tablet
occurred, as measured in exhaled breath. There was a statistically significant difference between
the time when pH 7.0 was reached and the lag time (185 vs 342 minutes, p = 0.002, non-
parametric test).
Fig 2. Mean (gastrointestinal residence and transit times determined with the IntelliCap system.Data are presented mean and standard deviation of
13 evaluable subjects (for CTT andWGTT n = 9).
doi:10.1371/journal.pone.0129076.g002
Ileo-Colonic Release of ColoPulse Tablets Confirmed with IntelliCap
PLOS ONE | DOI:10.1371/journal.pone.0129076 July 15, 2015 11 / 17
Discussion
This is the first study in humans combining release from ColoPulse tablets and in vivo gastro-
intestinal pH measurements using the IntelliCap system. There was no difference between
CAT (pH-data) and lag time (isotope data) found in this study which delivers proof that release
of ColoPulse tablets occurs in the ileo-colonic region. Furthermore the results show that release
from the ColoPulse tablet does not occur before an intestinal pH value of 7.0 is reached.
Several studies have been published with radiotelemetry capsules (RTC). Through the years
the functioning of RTCs improved considerably. The first RTCs were used in the 1970’s and
had logging intervals from 5 to 120 minutes to save battery capacity [8,10]. Furthermore high
data loss (75%) has been described [9]. Thereafter RTCs with shorter logging intervals up to 5
seconds became available and battery life improved considerably [16,17,19]. However in some
studies data loss was still described mostly attributed to the angle between the RTC and the
antenna [16]. In the current study with the IntelliCap system data loss was observed in three
subjects out of 15. This didn’t occur in the first 8 hours after intake of the capsule, when data
were also sent to the control center, but only when the subjects were at home and did not keep
their receiver close enough to the body. Therefore this event did not influence the outcome of
our study, because the IntelliCap capsule already passed the cecum at the time data loss
occurred. On the other hand, this shows that an overnight stay in a controlled facility is prefer-
able when longer pH profiling is needed.
The IntelliCap system was able to record complete gastrointestinal pH and temperature
profiles as well as derived transit-times from intake to excretion. The observed gastrointestinal
transit times for the small intestine and the colon are within the range of earlier published data
Fig 3. Example of pH-profile of the first 10 hours after intake of the IntelliCap capsule (subject 14).
doi:10.1371/journal.pone.0129076.g003
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of healthy volunteers, only the median GRT appeared to be increased [10,25]. Published data
collected with RTC and dosage forms labeled with gamma emitting radionuclides mention an
average GRT of about 1 h in fasted, healthy volunteers while we observed an average gastric
residence time of 1:30 h in the evaluable subjects. A likely explanation is the intake of the tab-
lets with apple juice, since it is known that food increases the GRT of pharmaceutical dosage
forms [25]. Due to its caloric content apple juice apparently also has a delaying effect. However
in this study, the apple juice was given to get the same study design as previous studies with
ColoPulse formulations. This was done to be able to compare the functioning of ColoPulse tab-
lets used in this study with capsules which were used in previous studies. In the future Colo-
Pulse formulations can also be administered with water.
All subjects showed an elevated gastric pH (pH 3–4) immediately after administration prob-
ably due to administration with apple juice, which decreased to a more acidic level of around
pH 1.6 in about 30 minutes. Because in our study the determination of the location of the Intel-
liCap capsule was only based on pH, pH values of the different segments of the small intestine
and colon could not be determined. The median pH values of the stomach, small intestines and
colon as observed in the majority of subjects are consistent with published data from fasted,
healthy volunteers [7].
No difference was found between the colon arrival time based on the 13C-isotope signal (lag
time of ColoPulse tablets) and pH-measurements (from IntelliCap system). This proves the
site-specific release of the active substance from the ColoPulse tablets in the ileo-colonic region.
Fig 4. Summary of pH in the stomach, small intestine and colon asmeasured with the IntelliCap system. Data are presented as mean and standard
deviation of 15 evaluable subjects.
doi:10.1371/journal.pone.0129076.g004
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Simultaneous migration of the ColoPulse tablet and the IntelliCap capsule after leaving the
stomach is supported by the literature. According to Davis et al [25] no difference in intestinal
transit times was seen between solid dosage forms with the same size of ColoPulse tablets and
the IntelliCap capsule. Gastric emptying of large single unit systems however, was highly influ-
enced by the presence of food in the stomach. Even a light breakfast delayed emptying in some
subjects. This may explain the increased stomach residence time of the IntelliCap capsule in
two subjects as seen in the current study. In these subjects colon arrival time and bioavailability
based on isotope signal were within the normal range. However the relatively large IntelliCap
capsule was retained in the stomach for respectively 17 and 21 h, probably because they
returned to their “normal”meal intakes when the IntelliCap capsule was still in the stomach.
After pylorus passage of these two IntelliCap capsules intestinal transit times were comparable
to those of the other subjects.
In this study we observed no relation between the lag-time of a ColoPulse tablet and the
time when pH 7.0 was reached or the CAT. However, in none of the subjects release from the
ColoPulse tablet occurred before pH 7.0 was reached.
The difference between the time when pH 7.0 was reached and the CAT was approximately
2.5 hours, supporting the fact that release occurs in the distal ileum and colon. Remarkably,
this difference in time is relatively large and differs from parameters used in vitro dissolution
tests that were performed with the ColoPulse tablets in the gastrointestinal simulation system
(GISS) [26]. We use this in vitro test for quality control of ColoPulse tablets and normally dis-
solution of the coating and subsequent release occurs within 30 minutes after raising pH from
Fig 5. Colon arrival time based on pH (-) corresponds with release of 13C (♦) (subject 14). See also Fig 4 for the first 10 hours.
doi:10.1371/journal.pone.0129076.g005
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6.8 to 7.5. However, the volumes of intestinal fluid in vivo differ from the volumes used in the
GISS. According to Schiller et al [27] the fluid volume of the small intestine has a maximum of
319 mL while the volume in this stage of the GISS is as high as 940 mL. Furthermore the fluid
is not distributed homogenously along the small intestine in vivo with water pockets and “dry”
segments randomly scattered. This contributes to the relatively slow dissolution of the Eudra-
git-S coating and is probably the cause of the relatively large difference between the time point
at which pH 7 was reached and the CAT. The clinical relevance of this phenomenon seems to
be limited because median bioavailability was 82%.
Conclusion
Based on the combined data from the IntelliCap system and the urea-isotope signal from a
ColoPulse tablet as obtained in this study in healthy volunteers it can be concluded that release
from ColoPulse tablets indeed occurs in the distal ileum and colon and after pH 7.0 is reached.
This supports our earlier observations and confirms that the ColoPulse system is a promising
delivery system for site-specific delivery and local therapy in inflammatory bowel diseases pres-
ent in the distal ileum and colon.
Fig 6. Difference (delta T) between lag-time (based on isotope signal) and CAT (based on pH) for each subject (n = 12).
doi:10.1371/journal.pone.0129076.g006
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